Patiromer vs. Placebo to Enable Spironolactone in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): Results in Prespecified Subgroups (2019)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.cardfail.2019.11.010
Publication URI: http://dx.doi.org/10.1016/j.cardfail.2019.11.010
Type: Journal Article/Review
Parent Publication: Journal of Cardiac Failure
Issue: 11